Back to Search
Start Over
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors
- Source :
- Stanley, B, Hollis, R, Nunes, H, Towler, J D, Yan, X, Rye, T, Dawson, C, Mackean, M J, Nussey, F, Churchman, M, Herrington, C & Gourley, C 2018, ' Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors ', Gynecologic Oncology . https://doi.org/10.1016/j.ygyno.2018.11.030
- Publication Year :
- 2018
-
Abstract
- Objectives. The role of endocrine therapy (ET) in high grade serous ovarian carcinoma (HGSOC) is poorly defined due to the lack of phase III data and significant heterogeneity of clinical trials performed. In this study, we sought to identify predictive factors of endocrine sensitivity in HGSOC. Methods. HGSOC patients who received at least four weeks of ET for relapsed disease following one line of chemotherapy at the Edinburgh Cancer Centre were identified. Exclusion criteria were use of endocrine therapy as maintenance therapy or of unknown duration. Duration of therapy and best CA125 response as per modified GCIG criteria were recorded. Oestrogen receptor (ER) histoscore, treatment free interval, prior lines of chemotherapy, and type of ET were evaluated as predictive factors. Results. Of 431 patients identified, 269 were eligible (77.0 % letrozole, 18.6% tamoxifen, 2.2% megesterol acetate, 2.2% other). The median duration of therapy was 126 days (range 28-1427 days). 32.7% remained on ET for ≥180 days and 14.1% for ≥365 days. The CA125 response and clinical benefit rates (response or stable disease) were 8.1% and 40.1% respectively. ER histoscore >200 (P=0.0016) and a treatment free interval of ≥180 days (P200 and a treatment free interval of ≥180 days are most likely to derive benefit.
- Subjects :
- Adult
0301 basic medicine
Oncology
medicine.medical_specialty
Antineoplastic Agents, Hormonal
medicine.medical_treatment
03 medical and health sciences
0302 clinical medicine
Maintenance therapy
Predictive Value of Tests
Internal medicine
Humans
Medicine
Endocrine system
Aged
Retrospective Studies
Aged, 80 and over
Ovarian Neoplasms
Chemotherapy
business.industry
Megestrol Acetate
Letrozole
Membrane Proteins
Obstetrics and Gynecology
Middle Aged
medicine.disease
Cystadenocarcinoma, Serous
Clinical trial
Tamoxifen
Serous fluid
030104 developmental biology
Receptors, Estrogen
CA-125 Antigen
030220 oncology & carcinogenesis
Female
Neoplasm Grading
business
Ovarian cancer
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Stanley, B, Hollis, R, Nunes, H, Towler, J D, Yan, X, Rye, T, Dawson, C, Mackean, M J, Nussey, F, Churchman, M, Herrington, C & Gourley, C 2018, ' Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors ', Gynecologic Oncology . https://doi.org/10.1016/j.ygyno.2018.11.030
- Accession number :
- edsair.doi.dedup.....01a1d46e123f20ac0d0e0d450192b361